x

VALIDOGEN News

101 31.01.2023

Meet us at  

Upcoming online conferences & exhibitions
Details
102 15.12.2021

Spotlight on VALIDOGEN’s strain and process development program

Spotlight on microbioreactors supporting Pichia protein production strain selection and bioreactor cultivation process development
Details
103 16.03.2021

VALIDOGEN to present at PICHIA 2021, online conference, March 24 - April 1

Pichia 2021, online conference "Don't miss latest insights into UNLOCK PICHIA technology developments"
Details
104 18.06.2020

New case study on VHH antibody expression underlines the power of UNLOCK PICHIA

We conducted a series of case studies, demonstrating the yield-enhancing effects of applying different toolbox elements of VALIDOGEN's Pichia ...
Details
105 05.06.2019

Spotlight on high-yield VHH expression using UNLOCK PICHIA

Benefit from the economic advantages of enhanced VHH production arising from the use of UNLOCK PICHIA
Details
106 22.10.2018

VTU Technology is now VALIDOGEN

VTU Technology is now VALIDOGEN
Details
107 26.06.2017

What About Pichia?  

Read our latest article "What about Pichia"  reviewing recent advances in optimising Pichia  European Biopharmaceutical Review July 2017, ...
Details
108 24.05.2016

Evercyte and VTU Technology collaborate on development of recombinant media supplements

Launch of first joint product – VEGF 165 for cell culture applications 
Details
111 11.04.2016

VTU Technology and Biomay have signed license agreement

Biomay to apply VTU Pichia strains for the production of recombinant allergens  
Details
113 03.12.2014

VTU Technology and RCT Announce Partnership

VTU Technology to offer unique combination of technologies for the high-level production of proteins with human-like glycosylation using Pichia ...
Details
114 04.07.2013

From Consulting Engineers to Technology Company

With more than 300 employees and 15 sites, VTU is now competing in the premier league of technology service providers.
Details
115 27.11.2012

VTU Technology and Minapharm Pharmaceuticals enter into development and license agreement

VTU Technology and Minapharm Pharmaceuticals announced today, that they have entered into a licensing agreement to develop a therapeutic, recombinant ...
Details
117 18.09.2012

DNA2.0 taps VTU Technology as Research Partner for Industrial Scale Protein Expression

DNA2.0 and VTU to Develop an Optimized Gene Design for Pichia Pastoris 
Details
118 04.01.2012

Almac and VTU Technology form collaboration - broader range of contract services

Almac and VTU Technology form collaboration to provide customers with high yielding, fast-track generation of site-specific modified products
Details
119 04.12.2011

VTU Technology Launches Breakthrough Technology for High Level Methanol-free Protein Expression

VTU Technology, a leading contract research and development company providing services for the fast-track generation of high-performance industrial ...
Details
120 20.11.2011

Collaboration of Boehringer Ingelheim and VTU Technology in Technology and Marketing

Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive ...
Details
X
KEEP in TOUCH
Sign up to our mailing list to keep up with latest developments and information around Pichia based protein expression.
GET in TOUCH
X
Welcome to VALIDOGEN!
Would you like us to contact you personally?
REQUEST NOW

News

Meet us at  

Upcoming online conferences & exhibitions
Details

Spotlight on VALIDOGEN’s strain and process development program

Spotlight on microbioreactors supporting Pichia protein production strain ...
Details

Downloads

Company folder and brochures

All downloads
Tablet Potrait-Mode gerade in Arbeit, bitte drehen Sie das Tablet in den Landscape-Mode.